1. India Stocks

  2. •

    Process industries

  3. •

    Containers/Packaging
Bilcare Ltd

Bilcare Ltd

83.85
INR
-1.71
(-2.00%)
-5.65EPS
18.90P/E
1.47BMarket Cap
Bilcare Ltd
NSE:BI
(National Stock Exchange of India)

Recent

price

83.85

P/E

ratio

18.90

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
971.14
1,546.72
1,506.35
1,300.47
1,143.46
1,103.86
1,118.24
1,177.53
1,270.25
773.73
260.96
353.78
409.7
313.59
329.62
306.87
328.39
Revenue per Share
62.65
58
16.82
-48.14
-91.76
-36.04
-35.9
-85.43
-193.28
-43.97
-8.95
-5.35
6.39
-14.12
-0.33
0.73
3.3
Basic EPS, GAAP
-289.8
-130.18
-342.7
-66.96
-133.85
-10.12
65.89
-49.25
38.33
108.8
27.93
15.53
-268.68
-24.32
27.11
49.68
- -
Free Cash Flow per Basic Share
2.81
3.49
2.32
- -
- -
0.49
0.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
452.69
566.82
562.94
562.25
312.84
302.72
260.59
169.83
-29.66
45.99
36.66
31.91
225.37
89.59
90.98
83.55
- -
Book Value per Share
375.37
452.8
442.7
417.06
187.72
124.63
99.11
-9.51
-200.43
35.25
29.83
26.5
216.8
84.3
86.21
80.3
- -
Tangible Book Value per Share
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
Basic Weighted Avg Shares
22,866
36,418
35,467
30,620
26,923
25,991
26,329
27,725
29,908
18,218
6,144
8,330
9,646
7,384
7,761
7,225
7,730
Sales/Revenue/Turnover
10.43
10.02
7.53
3.34
-0.2
2.69
0.58
-8.11
-6.97
-10.51
1.4
2.54
2.05
-0.52
4.08
4.6
4.83
Operating Margin (%)
9,095
1,998
1,485
3,229
32
1,636
1,769
4,162
3,784
2,388
455
393
378
449
181
198
331
Depreciation Expense
1,475
1,366
396
-1,133
-2,160
-849
-845
-2,011
-4,551
-1,035
-211
-126
150
-332
-8
17
78
Net Income, GAAP
24.99
25.69
24.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
74.39
- -
- -
- -
- -
Effective Tax Rate (%)
6.45
3.75
1.12
-3.7
-8.02
-3.26
-3.21
-7.25
-15.22
-5.68
-3.43
-1.51
1.56
-4.5
-0.1
0.24
1
Profit Margin (%)
9,536
13,349
10,223
10,582
4,002
1,487
432
-10,453
-11,870
540
239
180
46
611
33
611
- -
Working Capital
11,997
13,032
17,695
18,817
17,532
18,926
18,012
7,410
7,454
5,588
5,299
5,369
5,157
5,454
4,704
4,600
- -
LT Debt
11,147
13,867
13,790
13,764
7,940
7,716
6,760
4,633
-58
1,762
1,642
1,613
7,040
556
896
741
- -
Total Equity
9.4
10.65
6.42
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.76
- -
- -
- -
- -
Return on Invested Capital (%)
11.76
8.61
4.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.5
- -
- -
- -
- -
Return on Capital (%)
15.22
11.38
2.98
-8.56
-20.97
-11.71
-12.75
-39.69
- -
- -
-21.66
-15.6
4.97
-8.96
-0.37
0.84
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,604
- -
LT Borrowings
- -
4,497
- -
LT Finance Leases
- -
103
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
- -
- -
1,467

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,533
- -
Cash, Cash Equivalents & STI
- -
525
- -
Accounts Receivable, Net
- -
1,080
- -
Inventories
- -
1,148
- -
Total Current Liabilities
- -
2,922
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,604
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-299.65%
57.29%
-17.28%
Free Cash Flow
-308.77%
-418.75%
83.23%
Net Income, GAAP
-89.2%
-199.78%
-320.57%
Sales/Revenue/Turnover
-6.48%
5.23%
-6.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,941
2,017
1,981
1,940
7,761
2026
1,864
1,782
1,813
1,877
7,225
2027
2,259
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-2.71
-6.81
-3.05
7.47
-0.33
2026
1.34
-5.25
-2.53
5.68
0.73
2027
5.39
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Segezha (MOEX:SGZH)
Amcor plc (NYSE:AMCR)
Duran Dogan Basim ve Ambalaj Sanayi A.S. (BIST:DURDO)
Isiklar Enerji ve Yapi Holding Anonim Sirketi (BIST:IEYHO)
PT Abadi Nusantara Hijau Investama Tbk (IDX:PACK)
UFlex Limited (NSE:UFLEX)
Business
Bilcare Limited (BI.BO), founded in 1987 and headquartered in Pune, India, operates as a holding company providing pharmaceutical packaging research solutions, global clinical services, research and development services, and anti-counterfeit technologies to the global pharmaceutical industry; its core products and services include specialty polymer films such as blister films, laminates, high-barrier products like Ultra Tx and Armour, and eco-friendly options like Optra; aluminum foils encompassing child-resistant (CR) foils, lidding foils, and blister foils; clinical trial supply management featuring manufacturing and packaging of investigational medicinal products (IMPs) and placebos, primary and secondary packaging with blinding techniques, interactive web response systems (IWRS), worldwide distribution, returns, and destructions; and R&D offerings such as formulation stability studies, blister/foil design and development, analytical research, packaging trials, pharmaceutical brand innovation, and market studies. The company serves pharmaceutical manufacturers worldwide across over 100 countries, with manufacturing facilities in Pune and Nashik boasting 50,000 tonnes annual capacity, ISO Class 8 clean rooms, and compliance with global standards including USFDA, EU Pharmacopoeia, USP 661.1, REACH, and DMF filings; it emphasizes its novel 5Cs approach—Convenience, Communication, Compliance, Child-Resistant, and Counterfeiting protection—delivered through barrier properties against moisture/light/gases, high-speed machinability, printability, and embedded security features. In March 2023, Bilcare completed a major strategic shift by transferring its pharmaceutical packaging innovation (PPI) business to Caprihans India Limited via a slump sale for Rs 213 crore in redeemable preference shares, enabling the company to become debt-free, reduce overheads, and refocus on high-growth areas including global clinical supplies, R&D services, and anti-counterfeit solutions like nonClonableID (nCID) technologies; this consolidation enhances synergies within the group while positioning Bilcare for improved profitability and global expansion in clinical services.